InnoCan Pharma (TSE:INNO)

:INNO

INNO

InnoCan Pharma

RESEARCH TOOLSreports

InnoCan Pharma (INNO) Price & Analysis

22 Followers

INNO Stock Chart & Stats

C$7.50

C$0.01(5.26%)

At close: Jan 08 4:00 PM EST

C$7.50

C$0.01(5.26%)

Day’s Range― - ―

52-Week RangeC$5.76 - C$21.00

Previous CloseN/A

Volume118.77K

Average Volume (3M)920.00

Market Cap

C$29.96M

Enterprise ValueC$15.73M

Total Cash (Recent Filing)C$6.69M

Total Debt (Recent Filing)C$930.00K

Price to Earnings (P/E)―

Beta-0.35

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.62

Shares Outstanding4,498,772

10 Day Avg. Volume392

30 Day Avg. Volume920

Financial Highlights & Ratios

PEG Ratio0.48

Price to Book (P/B)3.90

Price to Sales (P/S)0.82

P/FCF Ratio45.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage and solid positive equity provide financial resilience, lowering refinancing and solvency risk. A stronger capital base supports continued R&D and product development spending and preserves optionality for strategic moves over the next 2–6 months.

Improved 2025 Cash GenerationA shift to positive operating and free cash flow increases internal funding capacity and reduces near-term dilution risk. If sustained, this improves runway for commercialization and supports execution of strategic plans over the medium term.

Proprietary Cannabinoid Delivery FocusA focused, proprietary delivery-platform strategy in cannabinoid therapeutics creates potential differentiation and product moat versus commodity suppliers. Structural demand for targeted cannabinoid formulations can support durable revenue if clinical and commercial adoption progress.

Bears Say

Ongoing Net LossesPersistent net losses limit retained-capital accumulation and increase reliance on external funding to sustain growth. Continued unprofitability compresses strategic flexibility and heightens execution risk if cash generation falters in coming quarters.

Cooling Revenue MomentumAfter rapid prior scaling, a top-line decline signals weaker demand or execution challenges. Slower revenue growth impairs operating leverage, threatens margin expansion potential, and raises questions about the sustainability of past growth trends.

Inconsistent Cash Flow Track RecordWhile 2025 shows positive cash flow, the prior multi-year cash burn record indicates volatility in cash generation. Irregular FCF raises refinancing and dilution risk if positive cash trends reverse, challenging long-term self-funding of operations and R&D.

InnoCan Pharma News

Innocan Pharma Secures Additional Insider Debenture Financing Ahead of Planned U.S. Offering

InnoCan Pharma ( ($TSE:INNO) ) has provided an update. Innocan Pharma plans to issue an additional US$200,000 debenture...

5d ago

Innocan Pharma Secures Insider Debenture Financing Ahead of Planned U.S. Listing

InnoCan Pharma ( ($TSE:INNO) ) has issued an update. Innocan Pharma plans to issue a US$450,000 secured debenture...

25d ago

Innocan’s Long-Acting CBD Injection Shows Superiority to Placebo in Canine Pain Trial

InnoCan Pharma ( ($TSE:INNO) ) has issued an announcement. Innocan Pharma reported that its liposomal synthetic cannabidiol (LPT-CBD)...

2M ago

Innocan Pharma Targets NYSE American Listing With Concurrent Offering

The latest announcement is out from InnoCan Pharma ( ($TSE:INNO) ). Innocan Pharma Corporation plans to list its...

2M ago

Innocan Pharma Targets NYSE American Listing with Concurrent Securities Offering

InnoCan Pharma ( ($TSE:INNO) ) has shared an update. Innocan Pharma Corporation plans to list its common shares...

3M ago

Innocan Pharma Unveils Promising Advances in CBD Drug Delivery Platform

InnoCan Pharma ( ($TSE:INNO) ) has provided an announcement. Innocan Pharma announced promising preliminary findings regarding its liposomal...

4M ago

Innocan Pharma Files Amended Registration for U.S. Public Offering

InnoCan Pharma ( ($TSE:INNO) ) has provided an announcement. Innocan Pharma has announced the public filing of an...

4M ago

Innocan Pharma Reports 2025 Financial Results

Innocan Pharma Corporation ( ($INNPF) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

Innocan Pharma Reports Q3 2025 Results and Advances Drug Delivery Platform

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma reported its Q3 2025 financial results, showing...

4M ago

Innocan Pharma’s LPT-CBD Shows Promising Results in Pain Relief Study

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma has published promising results from a study...

4M ago

INNO FAQ

What was InnoCan Pharma’s price range in the past 12 months?

InnoCan Pharma lowest stock price was C$5.76 and its highest was C$21.00 in the past 12 months.

What is InnoCan Pharma’s market cap?

InnoCan Pharma’s market cap is C$29.96M.

When is InnoCan Pharma’s upcoming earnings report date?

InnoCan Pharma’s upcoming earnings report date is Jun 01, 2026 which is in 57 days.

How were InnoCan Pharma’s earnings last quarter?

InnoCan Pharma released its earnings results on Mar 30, 2026. The company reported C$0.618 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.618.

Is InnoCan Pharma overvalued?

According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InnoCan Pharma pay dividends?

InnoCan Pharma does not currently pay dividends.

What is InnoCan Pharma’s EPS estimate?

InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InnoCan Pharma have?

InnoCan Pharma has 4,498,772 shares outstanding.

What happened to InnoCan Pharma’s price movement after its last earnings report?

InnoCan Pharma reported an EPS of C$0.618 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.062%.

Which hedge fund is a major shareholder of InnoCan Pharma?

Currently, no hedge funds are holding shares in TSE:INNO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InnoCan Pharma

InnoCan Pharma (INNO) is a biotechnology company focused on developing innovative therapeutic solutions leveraging cannabinoid-based technologies. The company operates primarily in the pharmaceutical and wellness sectors, with a core emphasis on creating advanced treatments for various medical conditions, including dermatological ailments and neurological disorders. InnoCan Pharma is known for its proprietary delivery systems that enhance the bioavailability of cannabinoids, aiming to revolutionize how these compounds are utilized in medical applications.